Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2009-02-26 Major Shareholding Noti…
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2009
Major Shareholding Notification
2009-02-26 English
Major Shareholding Notification 2009
Major Shareholding Notification
2009-02-20 English
EQUITY 11 5TH TRANCHE
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 18, 2009. It reports an unregistered sale of equity securities (Convertible Preferred Shares and warrants) to a purchaser, including details of the transaction and references to prior filings. The content focuses on a capital raising event and changes in the company's capital structure. There are no financial statements or comprehensive financial data presented, nor is it an earnings release or management discussion. The document is a regulatory announcement about financing activity, specifically an equity sale. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive information about the financing event, so it is not merely a report publication announcement or a regulatory filing fallback.
2009-02-18 English
FORM 4
Director's Dealing
2009-02-13 English
EQUITY 11 4TH TRANCHE
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 11, 2009. It reports an unregistered sale of equity securities (Convertible Preferred Shares) pursuant to a Securities Purchase Agreement. The content focuses on a financing transaction involving equity securities and does not contain comprehensive financial statements or detailed financial performance data. The document is not an annual or quarterly report, audit report, or earnings release. It is a regulatory filing reporting a capital raising event. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 3588 characters, which is consistent with a typical 8-K filing for such an event.
2009-02-12 English
FORM 4
Director's Dealing
2009-02-11 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.